Option chain shows key data for Actuate Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Actuate Therapeutics.

Actuate Therapeutics (NASDAQ:ACTU) Stock, Option Chain

Actuate Therapeutics

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Stock Movers

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AVGO

BURU

CADL

CHCI

EVGO

GXAI

LAES

LICN

LOOP

NFBK

PLRX

PRLH

RPTX

TRUG

Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Earnings

Actuate Reports Third Quarter 2010 Financial Results: EPS of $0.23

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics Inc

Health Care

Press Releases

Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas

Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research

Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma

Actuate Therapeutics to be Added to Russell 2000® Index

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

General

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

Alector

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

C4 Therapeutics

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genelux

Inventiva S.A. - American Depository Shares

Inventiva

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Lyell Immunopharma

Seres Therapeutics

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Puma Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

Vaxart

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

HC Wainwright & Co.

Actuate Sftwr

Comments

Actuate Therapeutics

Actuate Therapeutics (ACTU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga